Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
05 avr. 2024 04h36 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Tavapadon Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Global Dyskinesia Pipeline Insight 2024: In-depth Analysis on Emerging Drugs, Companies, and Ongoing Clinical Trials
27 févr. 2024 11h17 HE
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Dyskinesia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The global healthcare industry witnesses a pivotal...
Tardive Dyskinesia Therapeutics Market to Surge to USD 9.56 Billion by 2034, Exhibiting a CAGR of 9.31%
31 janv. 2024 07h42 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tardive Dyskinesia Therapeutics Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
01 août 2023 09h00 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Tardive Dyskinesia Therapeutics Market Size to Surpass USD 5.09 billion by 2030, exhibiting a CAGR of 9.1%
23 mai 2023 06h51 HE
|
Fortune Business Insights
Pune, India, May 23, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022 and is projected to grow...
Autism Spectrum Disorder Treatment Global Market Report 2022: Sector to Grow by 6.47% Annually Through 2033
29 déc. 2022 07h08 HE
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder Treatment Market by Treatment, Application, Distribution Channel, and by Region - Global Forecast to 2022-2033" report has...
Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight
29 août 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight Dyskinesia Pipeline constitutes 40+ key companies...
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
22 nov. 2021 10h00 HE
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
Global Parkinson's Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis
27 avr. 2021 06h28 HE
|
Research and Markets
Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering. The global PD...
Adamas Reports Third Quarter 2018 Financial Results
01 nov. 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...